Inify Laboratories – Final Results of the Repair Issue

Inify Laboratories completed a fully guaranteed repair issue of 2,304,563 shares at NOK 3.50 per share, raising gross proceeds of NOK 8,065,970.50; valid subscriptions covered 1,256,658 shares with the remaining 1,047,905 allocated to guarantors Monsun AS (898,204) and Auris AS (149,701). The offer shares were authorized by the extraordinary general meeting on 4 December 2025, payment is due on or about 25 March 2026, and delivery and commencement of trading on Euronext Growth Oslo are expected on or about 30 March 2026, with the financing fully backstopped by major-shareholder-controlled guarantors.

Analysis

Market structure: The repair issue (2,304,563 shares at NOK 3.50) was only ~54.5% subscribed by eligible shareholders (1,256,658 shares), leaving ~45.5% (1,047,905) placed with guarantor shareholders. That split signals limited open-market demand and a material near-term dilution (gross proceeds NOK 8.07m) that will likely compress free float and increase controlling owners’ stake, reducing public liquidity and increasing potential post-issuance volatility around payment (25 Mar 2026) and trading start (~30 Mar 2026).

Risk assessment: Key tail risks include FDI Act intervention if ownership crosses 10%+ thresholds (administrative fines and transaction delays), further capital raises if NOK 8m is insufficient for runway, and clinical/regulatory setbacks for AI-assisted pathology (customer contracts or reimbursements). Timewise, expect immediate muted market interest (days), price pressure at listing (weeks), and binary long-term outcomes (quarters) driven by contract wins, clinical validation, and revenue scale.

Trade implications: Direct play is short-biased on INIFY (Euronext Growth ticker INIFY) into the March-April window; liquidity constraints favor options if available—buy 3–6 month puts with strikes 20–30% below NOK 3.50. Pair strategy: short INIFY vs. long established diagnostics/medical-tech (Roche ROG.SW or Thermo Fisher TMO) to isolate idiosyncratic dilution risk while keeping sector upside.

Contrarian angles: Consensus overlooks that guarantors took shares without compensation — an implicit rescue that reduces immediate insolvency risk and preserves control, which could limit downside if owners inject more capital. If management secures a material UK/Nordic NHS contract or publishes validation data within 2–6 months, the stock could re-rate sharply; therefore downside is time-limited and event-driven rather than secular.

Key Decisions for Investors

• Initiate a tactical short position in INIFY equal to 2–3% of portfolio NAV (or equivalent notional) between now and 25 Mar 2026, target 20–35% downside post-listing, set hard stop-loss at +25% above entry; reduce position after 30 Mar 2026.
• If liquid options exist, buy 3–6 month INIFY puts (expiration Jun–Sep 2026) with strikes NOK 2.45–2.80 (~30%–20% below NOK 3.50); allocate no more than 0.5% NAV to premium risk — asymmetric payoff if market reprices dilution.
• Establish a 1–2% NAV long position in large-cap diagnostics/medtech (split equally ROG.SW and TMO) to hedge sector exposure and capture any positive re-rating from validation/contract catalysts while short INIFY.
• Avoid participating in any INIFY primary until the 10%+ ownership/FDI notification risk is clarified; require written confirmation of ISP clearance or board disclosure before increasing exposure beyond 1% ownership.